 WALTHAM, Mass. and HALLE Saale, Germany, Feb. 08, 2021 GLOBE NEWSWIRE -- Repligen Corporation NASDAQ:RGEN, a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH Navigo, a premier protein engineering company specializing in novel affinity ligand development, today announced that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines. 